{"transactions":[{"id":1214432,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":82187,"kind":"person","name":"Kim Robert Young","position":1,"cik":"0001971608","reported_name":"Kim Robert Young","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-10T23:58:05.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":92300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":92300,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":92300},"source":{"system":"sec-edgar","filing":"0000950170-25-036686","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017025036686/ownership.xml","form_type":"4"}},{"id":1654919,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":82187,"kind":"person","name":"Kim Robert Young","position":1,"cik":"0001971608","reported_name":"Kim Robert Young","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-08T01:32:33.000Z","date":"2024-02-05","kind":"exercise","planned":true,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":54000,"derivative":{"exercise_price":8.04,"expiration_date":"2032-08-31","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000950170-24-012456","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024012456/ownership.xml","form_type":"4"}},{"id":1654918,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":82187,"kind":"person","name":"Kim Robert Young","position":1,"cik":"0001971608","reported_name":"Kim Robert Young","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-08T01:32:33.000Z","date":"2024-02-05","kind":"exercise","planned":true,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 1, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":64000,"derivative":{"exercise_price":15.78,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000950170-24-012456","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024012456/ownership.xml","form_type":"4"}},{"id":1654917,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":82187,"kind":"person","name":"Kim Robert Young","position":1,"cik":"0001971608","reported_name":"Kim Robert Young","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-08T01:32:33.000Z","date":"2024-02-05","kind":"exercise","planned":true,"acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on the first anniversary measured from October 7, 2020 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest and become exercisable in equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":138000,"derivative":{"exercise_price":18.66,"expiration_date":"2030-11-08","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0000950170-24-012456","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024012456/ownership.xml","form_type":"4"}},{"id":1654916,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":82187,"kind":"person","name":"Kim Robert Young","position":1,"cik":"0001971608","reported_name":"Kim Robert Young","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-02-08T01:32:33.000Z","date":"2024-02-05","kind":"sale","planned":true,"acquired":false,"shares":552,"price":30.05,"value":16587.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on April 11, 2023."}],"balance_after":1043,"source":{"system":"sec-edgar","filing":"0000950170-24-012456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024012456/ownership.xml","form_type":"4"}},{"id":1654915,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":82187,"kind":"person","name":"Kim Robert Young","position":1,"cik":"0001971608","reported_name":"Kim Robert Young","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-02-08T01:32:33.000Z","date":"2024-02-05","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":30.05,"value":180300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on April 11, 2023."}],"balance_after":1595,"source":{"system":"sec-edgar","filing":"0000950170-24-012456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024012456/ownership.xml","form_type":"4"}},{"id":1654914,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":82187,"kind":"person","name":"Kim Robert Young","position":1,"cik":"0001971608","reported_name":"Kim Robert Young","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-02-08T01:32:33.000Z","date":"2024-02-05","kind":"exercise","planned":true,"acquired":true,"shares":6000,"price":8.04,"value":48240.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on April 11, 2023."}],"balance_after":7595,"source":{"system":"sec-edgar","filing":"0000950170-24-012456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024012456/ownership.xml","form_type":"4"}},{"id":1654913,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":82187,"kind":"person","name":"Kim Robert Young","position":1,"cik":"0001971608","reported_name":"Kim Robert Young","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-02-08T01:32:33.000Z","date":"2024-02-05","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":30.05,"value":180300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on April 11, 2023."}],"balance_after":1595,"source":{"system":"sec-edgar","filing":"0000950170-24-012456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024012456/ownership.xml","form_type":"4"}},{"id":1654912,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":82187,"kind":"person","name":"Kim Robert Young","position":1,"cik":"0001971608","reported_name":"Kim Robert Young","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-02-08T01:32:33.000Z","date":"2024-02-05","kind":"exercise","planned":true,"acquired":true,"shares":6000,"price":15.78,"value":94680.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on April 11, 2023."}],"balance_after":7595,"source":{"system":"sec-edgar","filing":"0000950170-24-012456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024012456/ownership.xml","form_type":"4"}},{"id":1654911,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":82187,"kind":"person","name":"Kim Robert Young","position":1,"cik":"0001971608","reported_name":"Kim Robert Young","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-02-08T01:32:33.000Z","date":"2024-02-05","kind":"sale","planned":true,"acquired":false,"shares":12000,"price":30.05,"value":360600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on April 11, 2023."}],"balance_after":1595,"source":{"system":"sec-edgar","filing":"0000950170-24-012456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024012456/ownership.xml","form_type":"4"}},{"id":1654910,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":82187,"kind":"person","name":"Kim Robert Young","position":1,"cik":"0001971608","reported_name":"Kim Robert Young","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-02-08T01:32:33.000Z","date":"2024-02-05","kind":"exercise","planned":true,"acquired":true,"shares":12000,"price":18.66,"value":223920.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on April 11, 2023."}],"balance_after":13595,"source":{"system":"sec-edgar","filing":"0000950170-24-012456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024012456/ownership.xml","form_type":"4"}},{"id":1712046,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":82187,"kind":"person","name":"Kim Robert Young","position":1,"cik":"0001971608","reported_name":"Kim Robert Young","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-13T21:05:13.000Z","date":"2023-12-11","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of December 11, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":250000,"derivative":{"exercise_price":14.42,"expiration_date":"2033-12-10","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000950170-23-070014","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017023070014/ownership.xml","form_type":"4"}}]}